09:51 uur 27-05-2021

Valbiotis heeft een lening voor innovatieondersteuning van € 1,25 miljoen toegekend door Bpifrance

  • Innovatielening Research & Development: € 750.000.
    Investeringskiemkrediet: € 500.000.

LA ROCHELLE, Frankrijk– (BUSINESS WIRE) – Regelgevend nieuws:

Valbiotis (FR0013254851 – ALVAL, PEA / SME in aanmerking) (Parijs: ALVAL), een onderzoeks- en ontwikkelingsbedrijf dat zich inzet voor wetenschappelijke innovatie voor het voorkomen en bestrijden van stofwisselingsziekten, kondigt de voortdurende steun van Bpifrance aan, met een lening voor innovatieondersteuning van € 1,25 miljoen.

Jocelyn PINEAU, CFO en lid van de Raad van Bestuur, licht toe: “Het bedrijf heeft zeer aanzienlijke vooruitgang geboekt in de eerste zes maanden van 2021. De fondsen van onze recente kapitaalverhoging en deze nieuwe innovatieleningen stellen onze financiële situatie veilig voor de nabije toekomst. , waardoor we ons met vertrouwen kunnen concentreren op de implementatie van onze wetenschappelijke en commerciële roadmap. Bij deze gelegenheid willen we de overheid, onze partners en al onze institutionele en individuele aandeelhouders bedanken voor hun steun. Bpifrance heeft naast Valbiotis gestaan ​​sinds het bedrijf werd opgericht in 2014. Deze langetermijnondersteuning is een enorme aanmoediging om onze innovatie-inspanningen voort te zetten, terwijl we onze onderzoeksprogramma’s versnellen.”

Valbiotis Granted a €1.25 Million Innovation Support Loan by Bpifrance

  • Research & Development innovation loan: €750,000.
  • Investment seed loan: €500,000.

LA ROCHELLE, France–(BUSINESS WIRE)– Regulatory News:

Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the continued support from Bpifrance, with a €1.25 million innovation support loan.

Jocelyn PINEAU, CFO and member of the Board of Directors, comments: “The Company has made very significant progress in the first six months of 2021. The funds from our recent capital increase and these new innovation loans secure our financial situation for the foreseeable future, allowing us to focus confidently on the implementation of our scientific and commercial roadmap. We would like to take this occasion to thank the public authorities, our partners, and all our institutional and individual shareholders for their support. Bpifrance has stood alongside Valbiotis since the company was created in 2014. This long-term support is a tremendous encouragement to continue our innovation efforts, as we accelerate our research programs.”

The €750,000 R&D innovation loan (“prêt innovation R&D”) has a 0.76% yearly flat rate and a 88-month duration, with a deferred capital amortization period followed by a linear amortization period, with a first payment in arrears scheduled for December 31, 2021.

The €500,000 investment seed loan has a 3.52% yearly flat rate and a 8-year duration, with a reimbursement over 20 quarterly payments, in arrears, after a 36-month deferred period during which only interests will be paid.

About Valbiotis

Valbiotis is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.

Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, based on a multi-target approach enabled by the use of plant-based ingredients.

Its products are intended to be licensed to players in the health sector.

Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France: Périgny, La Rochelle (17) and Riom (63).

Valbiotis is a member of the “BPI Excellence” network and has been recognized as an “Innovative Company” by the BPI label. Valbiotis has also been awarded “Young Innovative Company” status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.

For more information about Valbiotis, please visit: www.valbiotis.com

Name: Valbiotis

ISIN code: FR0013254851

Mnemonic code: ALVAL

EnterNext© PEA-PME 150

This press release contains forward-looking statements about Valbiotis’ objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and uncertainties, including those described in the Valbiotis registration document, approved by the French Financial Markets Regulator (AMF) on 31 July 2020 (application number R 20-018). This document is available on the Company’s website (www.valbiotis.com).

This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, Valbiotis’ shares or securities in any country.

Contacts

Corporate communication / Valbiotis

Carole ROCHER / Marc DELAUNAY

+33 5 46 28 62 58

media@valbiotis.com

Financial communication / Actifin

Stéphane RUIZ

+33 1 56 88 11 14

sruiz@actifin.fr

Check out our twitter: @NewsNovumpr